Matthias Wiesner
Merck & Co.
21 Papers
94 Citations
Matthias Wiesner is an academic researcher from Merck & Co.. The author has contributed to research in topics: Integrin & Carboxylic acid. The author has an hindex of 8, co-authored 21 publications. Previous affiliations of Matthias Wiesner include Merck KGaA & Humboldt State University.
Chat about Author
Papers
Dissecting the Role of Matrix Metalloproteinases (MMP) and Integrin αvβ3 in Angiogenesis In vitro: Absence of Hemopexin C Domain Bioactivity, but Membrane-Type 1-MMP and αvβ3 Are Critical
Riccardo E. Nisato,Ghamartaj Hosseini,Christian Sirrenberg,Georgina S. Butler,Thomas Crabbe,Andrew J. P. Docherty,Matthias Wiesner,Gillian Murphy,Christopher M. Overall,Simon L. Goodman,Michael S. Pepper +10 more
TL;DR: Investigating the dependency of in vitro angiogenesis on MMP-mediated extracellular proteolysis and integrin αvβ3–mediated cell adhesion in a three-dimensional collagen I model shows that endothelial cell invasion of collagen I gels is MT1-MMP and αv β3- dependent but M MP-2 independent and does not support a role for PEX in α vβ3 integrin binding or in modulating angiogenic in this system.
70
Synthesis and biological evaluation of integrin antagonists containing trans- and cis-2,5-disubstituted THF rings.
Frank Osterkamp,Burkhard Ziemer,Ulrich Koert,Matthias Wiesner,Peter Raddatz,Simon L. Goodman +5 more
TL;DR: A variety of compounds were tested as potential integrin antagonists in a receptor binding assay and the relative and absolute configuration of the chiral centers at the THF ring had a pronounced effect on the binding activity and selectivity.
30
Synthesis and biological evaluation of dianhydrohexitol integrin antagonists
TL;DR: In this article, the synthesis of a series of RGD mimetics is described, which have a 1,4:3,6-dianhydrohexitol core, a variable linker to a guanidino group, and a serine ether to mimic the carboxylic acid.
17
Patent
Glycinamide derivatives as raf-kinase inhibitors
Buchstaller Hans-Peter,Matthias Wiesner,Oliver Schadt,Amendt Christiane,Frank Zenke,Christian Sirrenberg,Grell Matthias +6 more
- 31 Jul 2003
TL;DR: In this article, the use of glycinamide derivatives of formula (I) as inhibitors of raf-kinase was discussed, and a method of treatment, comprising administering said pharmaceutical composition to a patient, was described.
14
Patent
Indol-3-yl derivatives and their use as integrin inhibitors
Simon Goodman,Gottschlich Rudolf,Matthias Wiesner +2 more
- 05 Jan 2001
TL;DR: Indol-3-yl derivatives of general formula (I), wherein A, B, X, R?1, R2, R3, R4, R5?, n or m have the meanings given in Claim 1, and the physiologically unobjectionable salts or solvates thereof are integrin inhibitors and can be used for combating thrombosis, myocardial infarcts, coronary heart diseases, arteriosclerosis, inflammations, tumours, osteoporosis, rheumatic arthritis, diabetic retinopathy, infections and resten
11